Lyell Immunopharma Reports 93% Overall Response Rate in Large B-Cell Lymphoma Trials
Written by Emily J. Thompson, Senior Investment Analyst
Source: Globenewswire
Updated: 1 hour ago0mins
- Clinical Response Rates: Ronde-cel demonstrated a 93% overall response rate and a 76% complete response rate in the 3L+ setting for large B-cell lymphoma, indicating its efficacy in high-risk patients and potential to improve patient outcomes.
- Survival Data: The median progression-free survival was reported at 18 months, showcasing ronde-cel's potential in extending patient survival, which may provide new options for future treatment regimens.
- Safety Profile: Among 69 patients, ronde-cel exhibited a manageable safety profile with no high-grade cytokine release syndrome observed, making it suitable for outpatient administration, which could enhance patient adherence to treatment.
- Key Trial Initiation: Lyell has initiated two pivotal clinical trials expected to enroll approximately 400 patients, evaluating the differentiated benefits of ronde-cel compared to existing therapies, potentially enhancing its market competitiveness.
LYEL.O
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on LYEL
Wall Street analysts forecast LYEL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for LYEL is 17.33 USD with a low forecast of 12.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
1 Buy
1 Hold
1 Sell
Hold
Current: 25.460
Low
12.00
Averages
17.33
High
20.00
Current: 25.460
Low
12.00
Averages
17.33
High
20.00
H.C. Wainwright
H.C. Wainwright
Neutral
maintain
$10 -> $20
2025-11-24
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$10 -> $20
2025-11-24
maintain
Neutral
Reason
H.C. Wainwright raised the firm's price target on Lyell Immunopharma to $20 from $10 and keeps a Neutral rating on the shares. The firm added colorectal cancer to the company's valuation.
Lucid Capital
Christopher Liu
Buy
initiated
$20
2025-09-26
Reason
Lucid Capital
Christopher Liu
Price Target
$20
2025-09-26
initiated
Buy
Reason
Lucid Capital analyst Christopher Liu initiated coverage of Lyell Immunopharma with a Buy rating and $20 price target. Lyell is a clinical-stage biotechnology company focused on developing potentially curative cell therapies for cancer patients, the analyst tells investors in a research note. The firm sees peak sales of $2.2B by 2039 for the company's lead asset ronde-cel in diffuse large B-cell lymphoma. The market is competitive, but there is room for several assets in the space given the meaningfully large opportunity, contends Lucid.
H.C. Wainwright
Mitchell Kapoor
Neutral
upgrade
$1 -> $10
2025-06-24
Reason
H.C. Wainwright
Mitchell Kapoor
Price Target
$1 -> $10
2025-06-24
upgrade
Neutral
Reason
H.C. Wainwright analyst Mitchell Kapoor raised the firm's price target on Lyell Immunopharma to $10 from $1 and keeps a Neutral rating on the shares. The firm adjusted the company's model to account for the 20-for-1 reverse split earlier this month.
HC Wainwright & Co.
Mitchell Kapoor
Hold
Reiterates
$1
2025-04-16
Reason
HC Wainwright & Co.
Mitchell Kapoor
Price Target
$1
2025-04-16
Reiterates
Hold
Reason
See All Ratings
About LYEL
Lyell Immunopharma, Inc. is a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with hematologic malignancies and solid tumors. The Company’s product candidates include LYL314 and LYL273. Its LYL314, which is in Phase I/II clinical development, is a dual-targeting CD19/CD20 CAR T-cell product candidate designed to increase complete response rates and prolong the duration of response as compared to the approved CD19-targeted CAR T-cell therapies and is under evaluation trial for the treatment of patients with relapsed and/or refractory large B-cell lymphoma. The Company has acquired the global rights to LYL273 (formerly GCC19CART), a novel autologous guanylyl cyclase-C (GCC)-targeted CAR T-cell product candidate for the treatment of metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
How did the company's recent strategic decisions impact its latest financial performance?
Can you explain the factors behind the recent changes in the company's stock price?
What are the expected impacts of current market trends on the company's future growth?
Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?